USA Drug Delivery Devices Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 22.78 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
USA Drug Delivery Devices Market Analysis
The US drug delivery devices market is expected to register a CAGR of 22.78% during the forecast period.
COVID-19 had a significant impact on the market studied during the early stages due to the rise in vaccination and immunization which utilized syringes and needles for administering the vaccines. As researchers developed vaccinations against COVID-19 that were widely administered intravenously, utilizing the syringe as a drug delivery device. As per the article published in 2022 by Drug Delivery and Translational Research journal, the success of mRNA vaccines demonstrated the critical role that drug delivery technologies had played in protecting billions of people from SARS-CoV-2. Administration of mRNA vaccines across the globe rise the demand for syringes as drug delivery devices, thereby increasing the market growth. As per the same source, the current mRNA development of COVID-19 vaccines is the outcome of years of basic research in the disciplines of nucleic acid therapy and drug delivery. Hence, an increase in research and development activities during and post-pandemic periods is expected to lead to growth in the post-pandemic period.
Factors such as the growing burden of chronic diseases and the developments related to drug delivery methods are expected to significantly contribute to the market growth. According to the 2022 data from the CDC, about six out of ten American individuals are suffering from chronic diseases, which are leading drivers of the nation's annual healthcare costs, amounting to around USD 4.1 trillion. Changing lifestyles, such as physical inactivity, consumption of a high-sugar diet, alcohol, smoking, etc., are responsible for the growing burden of the disease in the United States. As per the same source, physical inactivity ranges from 17.3 to 47.7 in the country. Thus, it is expected to drive the need for the management of these diseases, thereby boosting the market.
Product launches and collaboration in the United States regarding the market are likely to boost the market growth. In May 2022, Gland Pharma launched the cancer treatment drug Bortezomib, in an injection form, in the US market. The company launched the product in the US market through its partner, which received approval from the FDA. Bortezomib Injection is used to treat cancers, such as multiple myeloma and mantle cell lymphoma. Furthermore, in November 2022, Medtronic plc launched the Medtronic Extended infusion set, the first and only infusion set labeled for up to 7-day wear. An infusion set is tubing that delivers insulin from an insulin pump to the body and typically requires a set change every two to three days. Hence, considering the increased product launches in the United States, the drug delivery market is likely to grow over the forecast period.
Thus, due to the rise in the burden of chronic diseases and the increase in product launches, the market is anticipated to witness growth over the forecast period. However, the recalling of products by the FDA is expected to impede the market growth.
USA Drug Delivery Devices Market Trends
This section covers the major market trends shaping the USA Drug Delivery Devices Market according to our research experts:
Cancer Segment is Expected to Hold a Major Market Share in the United States Drug Delivery Devices Market
The cancer segment is expected to hold a significant share of the market studied. According to the ACS 2022 update, the number of new cancer cases is estimated to be 1.9 million in the United States in 2022. As per NCI, prostate, lung, and colorectal cancers accounted for an estimated 43% of all cancers diagnosed in men in 2020. For women, the three most common cancers are breast, lung, and colorectal; they accounted for 50% of all new cancer diagnoses in women in 2020. Hence, the high prevalence of cancer cases in the United States is likely to boost the market growth.
There is an immense need for a better delivery system in the treatment of cancer to improve the outcome. Recent developments concerning the drug delivery system in cancer are further expected to accelerate market growth. For instance, as per the August 2022 press release by the USFDA, the FDA approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer. This is the first approved therapy for patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer. Furthermore, increased government initiatives and funds to improve cancer drug delivery in the United States are boosting the market growth. For instance, as per the report of the NCI Budget 2022, the budget proposal included USD 50 million for the Childhood Cancer Data Initiative, as well as Cancer MoonshotSM funding, which was authorized in the 21st Century, Cures Act.
Thus, due to the growing burden of cancer cases, and the increase in healthcare expenditure the cancer segment is expected to record significant growth during the forecast period.
Injectable Segment is Anticipated to Witness Significant Growth Over the Forecast Period
The injectable segment is likely to observe significant growth in the market studied owing to factors such as an increase in vaccination and immunization in the country and the presence of a large patient population suffering from various chronic diseases. For instance, according to the WHO immunization data portal, the diphtheria-containing vaccine's fourth dosage (first booster) was administered to 81.6% of the population. With the increase in immunization, the utilization of syringes and needles also increases, which is expected to boost the segment's growth over the forecast period.
Furthermore, in June 2022, BD (Becton, Dickinson, and Co.) and Mitsubishi Gas Chemical Co. Inc. (MCG) signed a letter of intent to discuss a partnership to explore new ways to advance pre-fillable syringe technology for biologic drug delivery. The agreement stated that they are anticipated to investigate the development of Oxycapt, an innovation from MGC that integrates the best of plastic and glass for the plastic syringe.
The increased adoption of injectable drugs, technological advancements in syringes, and the growing number of vaccination and immunization programs are expected to drive the volume growth over the next few years. For instance, in January 2022, Nephron Pharmaceuticals Corporation launched the cyclic olefin copolymer syringe (COC). It has a glass-like appearance but is break-resistant and lightweight. COC syringes are suitable for a variety of medications, including highly viscous drugs, and provide an extended product shelf-life. The disconnected plunger allows for easier storage. Also, the expansion of facilities to produce syringes is anticipated to contribute to the growth of the market.
Hence, due to the rise in injectable product launches and the increase in vaccination coverage, the injectable segment is anticipated to witness growth over the forecast period.
USA Drug Delivery Devices Industry Overview
The US drug delivery devices market is highly competitive. The competitive landscape includes an analysis of a few international as well as local companies that hold market shares and are well known. Many of these companies are undertaking various strategies to maintain their market shares. The key players in the market are Bayer AG, Johnson & Johnson Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Merck & Co. Inc., Sanofi, Abbott Laboratories, and 3M.
USA Drug Delivery Devices Market Leaders
-
Bayer AG
-
F. Hoffmann-La Roche Ltd
-
Johnson & Johnson
-
Novartis AG
-
GSK PLC
*Disclaimer: Major Players sorted in no particular order
USA Drug Delivery Devices Market News
- October 2022: FDA approved FUROSCIX (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure.
- September 2022: Baxter International Inc., received the US FDA approval for the commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine). Norepinephrine is used to increase blood pressure in adult patients who have severe, acute hypotension.
USA Drug Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Chronic Diseases
4.2.2 Innovation in Drug Delivery Devices
4.3 Market Restraints
4.3.1 Product Recalls
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Route of Administration
5.1.1 Topical
5.1.2 Injectable
5.1.3 Oral
5.1.4 Other Routes of Administration
5.2 By Application
5.2.1 Cancer
5.2.2 Cardiovascular
5.2.3 Diabetes
5.2.4 Other Applications
5.3 By End Users
5.3.1 Hospitals
5.3.2 Ambulatory Surgical Centres
5.3.3 Other End Users
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Johnson & Johnson Inc.
6.1.3 Novartis AG
6.1.4 Pfizer Inc.
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 GSK PLC
6.1.7 Merck & Co. Inc.
6.1.8 Sanofi
6.1.9 Antares Pharma
6.1.10 3M
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
USA Drug Delivery Devices Industry Segmentation
Drug delivery devices or systems are the tools used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances in the body. The United States Drug Delivery Devices Market is Segmented by Route of Administration (Topical, Injectable, Oral, and Other Routes of Administration), Application (Cancer, Cardiovascular, Diabetes, and Other Applications), and End Users (Hospitals, Ambulatory Surgical Centres, and Other End Users). The report offers the value (in USD million) for the above segments.
| By Route of Administration | |
| Topical | |
| Injectable | |
| Oral | |
| Other Routes of Administration |
| By Application | |
| Cancer | |
| Cardiovascular | |
| Diabetes | |
| Other Applications |
| By End Users | |
| Hospitals | |
| Ambulatory Surgical Centres | |
| Other End Users |
USA Drug Delivery Devices Market Research FAQs
What is the current United States Drug Delivery Devices Market size?
The United States Drug Delivery Devices Market is projected to register a CAGR of 22.78% during the forecast period (2024-2029)
Who are the key players in United States Drug Delivery Devices Market?
Bayer AG, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Novartis AG and GSK PLC are the major companies operating in the United States Drug Delivery Devices Market.
What years does this United States Drug Delivery Devices Market cover?
The report covers the United States Drug Delivery Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the United States Drug Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
United States Drug Delivery Devices Industry Report
Statistics for the 2024 United States Drug Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. United States Drug Delivery Devices analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
